Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort study.
Antistaphylococcal Penicillin
Cefazolin
Cloxacillin
Endocarditis
Methicillin-susceptible Staphylococcus
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
received:
21
03
2024
accepted:
09
05
2024
medline:
29
5
2024
pubmed:
29
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
To compare the effectiveness and safety of cefazolin versus cloxacillin for the treatment of infective endocarditis (IE) due to methicillin-sensitive Staphylococci (MSS). Data were retrospectively collected on patients treated for a definite MSS endocarditis who received cefazolin or cloxacillin for at least 10 consecutive days in six French hospitals between January-1 2014 and December-31 2020. The primary endpoint was treatment failure defined as a composite of death within 90 days of starting antibiotherapy, or embolic event during antibiotherapy, or relapse of IE within 90 days of stopping antibiotherapy. We used Cox regression adjusted for the inverse probability of treatment weighting of receiving cefazolin. 192 patients were included (median age 67.8 years). IE was caused by S.aureus in 175 (91.1%) and by coagulase-negative staphylococci in 17 (8.9%). Ninety-four patients (48.9%) received cefazolin, and 98 (51%) received cloxacillin. 34 patients (34.7%) with cefazolin and 26 (27.7%) with cloxacillin met the composite primary endpoint, with no significant differences between groups (adjusted HR = 1.13, 95% CI 0.63 to 2.03). There were no significant differences in secondary efficacy endpoints or biological safety events. The effectiveness of cefazolin did not significantly differ from cloxacillin for the treatment of MSS endocarditis.
Identifiants
pubmed: 38806841
doi: 10.1007/s10096-024-04851-6
pii: 10.1007/s10096-024-04851-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C et al (2019) Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 14:40:3222–3232. https://doi.org/10.1093/eurheartj/ehz620
doi: 10.1093/eurheartj/ehz620
Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS et al (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. Arch Intern Med 9:169:463–473. https://doi.org/10.1001/archinternmed.2008.603
doi: 10.1001/archinternmed.2008.603
Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B et al (2012) Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis off Publ Infect Dis Soc Am 54:1230–1239. https://doi.org/10.1093/cid/cis199
doi: 10.1093/cid/cis199
Lalani T, Kanafani ZA, Chu VH, Moore L, Corey GR, Pappas P et al (2006) Prosthetic valve endocarditis due to coagulase-negative staphylococci: findings from the International collaboration on Endocarditis merged database. Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol 25:365–368. https://doi.org/10.1007/s10096-006-0141-z
doi: 10.1007/s10096-006-0141-z
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F et al (2015) 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-thoracic surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 21:36:3075–3128. https://doi.org/10.1093/eurheartj/ehv319
doi: 10.1093/eurheartj/ehv319
Schandiz H, Olav Hermansen N, Jørgensen T, Roald B (2015) Staphylococcus lugdunensis endocarditis following vasectomy – report of a case history and review of the literature. APMIS 123:726–729. https://doi.org/10.1111/apm.12396
doi: 10.1111/apm.12396
pubmed: 26058423
Sugiyama K, Watanuki H, Futamura Y, Matsuyama K Prosthetic valve endocarditis caused by silent infection of methicillin-resistant coagulase-negative staphylococci. BMJ Case Rep 2021 25;14:e236383. https://doi.org/10.1136/bcr-2020-236383
Rindone JP, Mellen CK (2018) Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Br J Clin Pharmacol 84:1258–1266. https://doi.org/10.1111/bcp.13554
doi: 10.1111/bcp.13554
pubmed: 29600576
pmcid: 5980628
Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J et al (2015) Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 59:5232–5238. https://doi.org/10.1128/AAC.04677-14
doi: 10.1128/AAC.04677-14
pubmed: 26077253
pmcid: 4538481
Weis S, Kesselmeier M, Davis JS, Morris AM, Lee S, Scherag A et al (2019) Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 25:818–827. https://doi.org/10.1016/j.cmi.2019.03.010
doi: 10.1016/j.cmi.2019.03.010
Bidell MR, Patel N, O’Donnell JN Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother 2018 1;73:2643–2651. https://doi.org/10.1093/jac/dky259
Loubet P, Burdet C, Vindrios W, Grall N, Wolff M, Yazdanpanah Y et al (2018) Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 24:125–132. https://doi.org/10.1016/j.cmi.2017.07.003
doi: 10.1016/j.cmi.2017.07.003
Lavergne A, Vigneau C, Polard E, Triquet L, Rioux-Leclercq N, Tattevin P et al (2018) Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review. Int J Antimicrob Agents 52:344–349. https://doi.org/10.1016/j.ijantimicag.2018.04.007
doi: 10.1016/j.ijantimicag.2018.04.007
pubmed: 29665445
Valour F, Karsenty J, Bouaziz A, Ader F, Tod M, Lustig S et al (2014) Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 58:746–755. https://doi.org/10.1128/AAC.02032-13
doi: 10.1128/AAC.02032-13
pubmed: 24247130
pmcid: 3910824
Nannini EC, Singh KV, Arias CA, Murray BE (2013) In vivo effects of Cefazolin, Daptomycin, and Nafcillin in Experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an Inoculum Effect against Cefazolin. Antimicrob Agents Chemother 57:4276–4281. https://doi.org/10.1128/AAC.00856-13
doi: 10.1128/AAC.00856-13
pubmed: 23796934
pmcid: 3754321
Wang SK, Gilchrist A, Loukitcheva A, Plotkin BJ, Sigar IM, Gross AE et al (2018) Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene types among Methicillin-Susceptible Staphylococcus aureus isolates from Four Major Medical Centers in Chicago. Antimicrob Agents Chemother 62:e00382–e00318. https://doi.org/10.1128/AAC.00382-18
doi: 10.1128/AAC.00382-18
pubmed: 29891607
pmcid: 6105856
Miller WR, Seas C, Carvajal LP, Diaz L, Echeverri AM, Ferro C et al (2018) The Cefazolin Inoculum Effect is Associated with increased mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia. Open Forum Infect Dis 15:ofy123. https://doi.org/10.1093/ofid/ofy123
doi: 10.1093/ofid/ofy123
Lecomte R, Bourreau A, Deschanvres C, Issa N, Le Turnier P, Gaborit B et al (2021) Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis 27:1015–1021. https://doi.org/10.1016/j.cmi.2020.08.044
doi: 10.1016/j.cmi.2020.08.044
Lefèvre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C et al (2021) Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol 40:2605–2616. https://doi.org/10.1007/s10096-021-04313-3
doi: 10.1007/s10096-021-04313-3
Davis JS, Turnidge J, Tong S (2018) A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 52:297–300. https://doi.org/10.1016/j.ijantimicag.2018.02.013
doi: 10.1016/j.ijantimicag.2018.02.013
pubmed: 29499317
CA-SFM / (2022) EUCAST: Société Française de Microbiologie Ed
Pc A An introduction to Propensity score methods for reducing the effects of confounding in Observational studies. Multivar Behav Res [ Internet] 2011 [cited 2024 22];46. doi: https://pubmed.ncbi.nlm.nih.gov/21818162/doi : https://doi.org/10.1080/00273171.2011.568786
Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GTH (2017) Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. Int J Epidemiol 14:45:1887–1894
Lee S, Song K-H, Jung S-I, Park WB, Lee SH, Kim Y-S et al Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect 2018 1;24:152–158. https://doi.org/10.1016/j.cmi.2017.07.001
McDanel JS, Roghmann M-C, Perencevich EN, Ohl ME, Goto M, Livorsi DJ et al (2017) Comparative effectiveness of Cefazolin Versus Nafcillin or Oxacillin for treatment of Methicillin-Susceptible Staphylococcus aureus infections complicated by Bacteremia: a Nationwide Cohort Study. Clin Infect Dis off Publ Infect Dis Soc Am 1:65:100–106. https://doi.org/10.1093/cid/cix287
doi: 10.1093/cid/cix287
Twilla JD, Algrim A, Adams EH, Samarin M, Cummings C, Finch CK Comparison of Nafcillin and Cefazolin for the treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia. Am J Med Sci 2020 1;360:35–41. https://doi.org/10.1016/j.amjms.2020.04.006
Chan L, Chan-Tompkins NH, Como J, Guarascio AJ (2020) Retrospective analysis of adverse drug events between Nafcillin Versus Cefazolin for treatment of Methicillin-Susceptible Staphylococcus aureus infections. Ann Pharmacother 54:662–668. https://doi.org/10.1177/1060028019897267
doi: 10.1177/1060028019897267
pubmed: 31888347
Angles E, Mouton C, Perino J, Remy A, Ouattara A (2018) Hypoprothrombinemia and severe perioperative haemorrhagic complications in cardiac surgery patients treated with high-dose cefazolin for infective endocarditis. Anaesth Crit Care Pain Med 37:167–170. https://doi.org/10.1016/j.accpm.2017.07.006
doi: 10.1016/j.accpm.2017.07.006
pubmed: 28870850
Dingle TC, Gamage D, Gomez-Villegas S, Hanson BM, Reyes J, Abbott A et al (2022) Prevalence and characterization of the Cefazolin Inoculum Effect in North American Methicillin-Susceptible Staphylococcus aureus isolates. J Clin Microbiol 2060:e0249521. https://doi.org/10.1128/jcm.02495-21
doi: 10.1128/jcm.02495-21
Nannini EC, Singh KV, Murray BE (2003) Relapse of type a beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis off Publ Infect Dis Soc Am 37(1):1194–1198. https://doi.org/10.1086/379021
doi: 10.1086/379021
Neuville M, El-Helali N, Magalhaes E, Radjou A, Smonig R, Soubirou J-F et al Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. Ann Intensive Care 2017 22;7:34. https://doi.org/10.1186/s13613-017-0255-8
Vareil M-O, Barret A, Vinclair C, Guerpillon B, Leyssene D, Jaouen A-C et al Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage. Infect Dis Now 2021 1;51:304–307. https://doi.org/10.1016/j.idnow.2020.11.015
Bourget M, Pasquie M, Charbonneau H, Bonnet E (2022) Comparable clinical course between coagulase-negative staphylococcal and Staphylococcus aureus Endocarditis. Infection 50:483–490. https://doi.org/10.1007/s15010-021-01738-y
doi: 10.1007/s15010-021-01738-y
pubmed: 35006535